Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Pilot dose-finding trial on interferon alpha in combination with ribavirinfor the treatment of chronic hepatitis C in patients not responding to interferon alone
Autore:
Puoti, M; Cadeo, GP; Putzolu, V; Forleo, MA; Barni, MC; Cristini, G; Rossi, S; Spinetti, A; Zaltron, S; Zanini, B; Quiros-Roldan, E; Paraninfo, G; Gargiulo, F; Carosi, G;
Indirizzi:
Brescia Hosp, Clin Infect & Trop Dis, Brescia, Italy Brescia Hosp Brescia Italy Hosp, Clin Infect & Trop Dis, Brescia, Italy Brescia Hosp, Dept Microbiol, Brescia, Italy Brescia Hosp Brescia ItalyBrescia Hosp, Dept Microbiol, Brescia, Italy Brescia Hosp, Div Infect Dis 1, Brescia, Italy Brescia Hosp Brescia Italy escia Hosp, Div Infect Dis 1, Brescia, Italy
Titolo Testata:
DIGESTIVE AND LIVER DISEASE
fascicolo: 2, volume: 33, anno: 2001,
pagine: 163 - 172
SICI:
1590-8658(200103)33:2<163:PDTOIA>2.0.ZU;2-X
Fonte:
ISI
Lingua:
ENG
Soggetto:
RANDOMIZED MULTICENTER TRIAL; CHRONIC ACTIVE HEPATITIS; PLUS RIBAVIRIN; CONSENSUS INTERFERON; THERAPY; VIRUS; EFFICACY; NONRESPONDERS; RETREATMENT; RESISTANT;
Keywords:
hepatitis C Virus; hepatitis C Virus kinetics; hepatitis C Virus-RNA;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
31
Recensione:
Indirizzi per estratti:
Indirizzo: Puoti, M Clin Malattie Infett & Trop, Piazzale Spedali Civili 1, I-25123 Brescia, Italy Clin Malattie Infett & Trop Piazzale Spedali Civili 1 Brescia Italy I-25123
Citazione:
M. Puoti et al., "Pilot dose-finding trial on interferon alpha in combination with ribavirinfor the treatment of chronic hepatitis C in patients not responding to interferon alone", DIG LIVER D, 33(2), 2001, pp. 163-172

Abstract

Background, Effectiveness of combination therapy with standard interferon alpha doses and ribavirin is far from being demonstrated in patients with hepatitis C non responders to interferon alpha monotherapy. Recent kinetic studies revealed that these doses may be suboptimal. Aims. To find the criteria for optimisation of the interferon dose, to be used in combination with ribavirin in patients with hepatitis C non responders to interferon alpha monotherapy. Patients. Sixty-three patients enrolled in a pilot controlled trial were treated for 6 months with ribavirin (1000-1200 mg daily) and were randomisedto concurrently receive interferon alpha;Ib for 6 months at: 3 Million Units thrice weekly [group A (21 patients)], 5 MU thrice weekly [group B (21 patients)] and 5 million units daily [group C (21 patients)]. Results. A sustained virological response was observed in: 1 patient from group A (5%), 2patients from group B (9%) and 8 patients from group C (38%; p=0.02 vs group A, p=0.03 vs group B). Side-effects were not significantly different between the 3 groups. Multivariate analysis showed that infection by hepatitisC virus genotypes 2 or 3 and interferon alpha dosage of 5 million units daily were independent predictors of sustained response. Conclusions, These results suggest that higher interferon doses administered daily in combination with ribavirin could be more effective in those patients with hepatitis C who had not responded to interferon alone.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/01/20 alle ore 07:32:25